Hallux

About:

Hallux develops a new topical dosage form and route of administration for treating onychomycosis.

Website: http://halluxinc.com/

Top Investors: Deerfield

Description:

Hallux is a privately held clinical-stage pharmaceutical company that develops a new topical dosage form and route of administration for treating onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well-tolerated. The company’s technology delivers high concentrations of the gold standard antifungal terbinafine directly and selectively to the site of infection without introducing it systemically, where it can affect the liver and interact with other drugs that patients may be taking. It was founded in 2012 and is headquartered in Laguna Hills, California.